Biomarkers for systemic lupus erythematosus - a focus on organ damage

被引:5
|
作者
Ding, Huihua [1 ,2 ]
Shen, Yiwei [1 ,2 ]
Hong, Soon-Min [1 ,2 ]
Xiang, Chunyan [1 ,2 ]
Shen, Nan [1 ,2 ,3 ,4 ,5 ,6 ,7 ,8 ,9 ]
机构
[1] Shanghai Jiao Tong Univ Sch Med SJTUSM, Renji Hosp, Dept Rheumatol, Shanghai, Peoples R China
[2] Shanghai Jiao Tong Univ Sch Med SJTUSM, Renji Hosp, Shanghai Inst Rheumatol, Shanghai, Peoples R China
[3] Shanghai Jiao Tong Univ, Renji Hosp, China Australia Ctr Personalized Immunol, Sch Med, Shanghai, Peoples R China
[4] Shanghai Jiao Tong Univ Sch Med SJTUSM, Renji Hosp, Shanghai Canc Inst, State Key Lab Oncogenes & Related Genes, Shanghai, Peoples R China
[5] Shenzhen Futian Hosp Rheumat Dis, Dept Rheumatol, Shenzhen, Peoples R China
[6] Cincinnati Childrens Hosp Med Ctr, Ctr Autoimmune Genom & Etiol CAGE, Cincinnati, OH USA
[7] Univ Cincinnati, Dept Pediat, Coll Med, Cincinnati, OH USA
[8] Shanghai Jiao Tong Univ, Collaborat Innovat Ctr Translat Med, Sch Med, Shanghai, Peoples R China
[9] Shanghai Jiao Tong Univ Sch Med SJTUSM, Renji Hosp, Dept Rheumatol, 145 Shandong M Rd, Shanghai 200001, Peoples R China
基金
中国国家自然科学基金;
关键词
Biomarker; systemic lupus erythematosus; cutaneous lupus erythematosus; lupus nephritis; neuropsychiatric systemic lupus erythematosus; MONOCYTE CHEMOATTRACTANT PROTEIN-1; URINARY SOLUBLE CD163; CEREBROSPINAL-FLUID; DISEASE-ACTIVITY; NEUROPSYCHIATRIC LUPUS; POTENTIAL BIOMARKER; RECEPTOR ANTIBODIES; ELEVATED LEVELS; LIGAND APRIL; RISK-FACTORS;
D O I
10.1080/1744666X.2023.2260098
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
IntroductionSystemic lupus erythematosus (SLE) is complex autoimmune disease with heterogenous manifestations, unpredictable disease course and response to treatment. One of the critical needs in SLE management is the identification of reliable biomarkers that can aid in early diagnosis, accurate monitoring of disease activity, and assessment of treatment response.Areas coveredIn the current review, we focus on the commonly affected organs (skin, kidney, and nervous system) in SLE to summarize the emerging biomarkers that show promise in disease diagnosis, monitoring and treatment response assessment. The subtitles within each organ domain were determined based on the most relevant and promising biomarkers for that specific organ damage.Expert opinionBiomarkers have the potential to significantly benefit the management of SLE by aiding in diagnosis, disease activity monitoring, prognosis, and treatment response assessment. However, despite decades of research, none has been validated and implemented for routine clinical use. Novel biomarkers could lead to the development of precision medicine for SLE, guide personalized treatment, and improve patient outcomes. Challenges in biomarker research in SLE include defining clear and clinically relevant questions, accounting for the heterogeneity of SLE, and confirming initial findings in larger, multi-center, multi-ethnic, independent cohorts that reflect real-world clinical scenarios.
引用
收藏
页码:39 / 58
页数:20
相关论文
共 50 条
  • [1] Autoimmunity and organ damage in systemic lupus erythematosus
    George C. Tsokos
    Nature Immunology, 2020, 21 : 605 - 614
  • [2] Autoimmunity and organ damage in systemic lupus erythematosus
    Tsokos, George C.
    NATURE IMMUNOLOGY, 2020, 21 (06) : 605 - 614
  • [3] ORGAN DAMAGE IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
    Zivkovic, V.
    Mitic, B.
    Stamenkovic, B.
    Milenkovic, S.
    Jovanovic, J.
    Aleksic, I.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 1240 - 1240
  • [4] Impact of Belimumab on Organ Damage in Systemic Lupus Erythematosus
    Urowitz, Murray B.
    Aranow, Cynthia
    Asukai, Yumi
    Bass, Damon L.
    Bruce, Ian N.
    Chauhan, Deven
    Dall'Era, Maria
    Furie, Richard
    Fox, Norma Lynn
    Gilbride, Jennifer A.
    Hammer, Anne
    Ginzler, Ellen M.
    Gonzalez-Rivera, Tania
    Levy, Roger A.
    Merrill, Joan T.
    Quasny, Holly
    Roth, David A.
    Stohl, William
    van Vollenhoven, Ronald
    Wallace, Daniel J.
    Petri, Michelle
    ARTHRITIS CARE & RESEARCH, 2022, 74 (11) : 1822 - 1828
  • [5] Predictors of Organ Damage in Systemic Lupus Erythematosus The Hopkins Lupus Cohort
    Petri, Michelle
    Purvey, Sneha
    Fang, Hong
    Magder, Laurence S.
    ARTHRITIS AND RHEUMATISM, 2012, 64 (12): : 4021 - 4028
  • [6] Possible novel biomarkers of organ involvement in systemic lupus erythematosus
    Su, Dinglei
    Liu, Rui
    Li, Xia
    Sun, Lingyun
    CLINICAL RHEUMATOLOGY, 2014, 33 (08) : 1025 - 1031
  • [7] Possible novel biomarkers of organ involvement in systemic lupus erythematosus
    Dinglei Su
    Rui Liu
    Xia Li
    Lingyun Sun
    Clinical Rheumatology, 2014, 33 : 1025 - 1031
  • [8] The contribution of antiphospholipid antibodies to organ damage in systemic lupus erythematosus
    Taraborelli, M.
    Leuenberger, L.
    Lazzaroni, M. G.
    Martinazzi, N.
    Zhang, W.
    Franceschini, F.
    Salmon, J.
    Tincani, A.
    Erkan, D.
    LUPUS, 2016, 25 (12) : 1365 - 1368
  • [9] RISK FACTORS FOR ORGAN DAMAGE IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
    Zivkovic, V.
    Mitic, B.
    Cvetkovic, T.
    Stamenkovic, B.
    Nedovic, J.
    Milenkovic, S.
    Aleksic, I.
    ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 1107 - 1107
  • [10] Sphingolipids and Diagnosis, Prognosis, and Organ Damage in Systemic Lupus Erythematosus
    Harden, Olivia C.
    Hammad, Samar M.
    FRONTIERS IN IMMUNOLOGY, 2020, 11